Abstract:Over the last decade, hydrogen sulfide (H2S) has emerged as an important endogenous gasotransmitter in mammalian cells and tissues. Similar to the previously characterized gasotransmitters nitric oxide and carbon monoxide, H2S is produced by various enzymatic reactions and regulates a host of physiologic and pathophysiological processes in various cells and tissues. H2S levels are decreased in a number of conditions (e.g., diabetes mellitus, ischemia, and aging) and are increased in other states (e.g., inflammation, critical illness, and cancer). Over the last decades, multiple approaches have been identified for the therapeutic exploitation of H2S, either based on H2S donation or inhibition of H2S biosynthesis. H2S donation can be achieved through the inhalation of H2S gas and/or the parenteral or enteral administration of so-called fast-releasing H2S donors (salts of H2S such as NaHS and Na2S) or slow-releasing H2S donors (GYY4137 being the prototypical compound used in hundreds of studies in vitro and in vivo). Recent work also identifies various donors with regulated H2S release profiles, including oxidant-triggered donors, pH-dependent donors, esterase-activated donors, and organelle-targeted (e.g., mitochondrial) compounds. There are also approaches where existing, clinically approved drugs of various classes (e.g., nonsteroidal anti-inflammatories) are coupled with H2S-donating groups (the most advanced compound in clinical trials is ATB-346, an H2S-donating derivative of the non-steroidal anti-inflammatory compound naproxen). For pharmacological inhibition of H2S synthesis, there are now several small molecule compounds targeting each of the three H2S-producing enzymes cystathionine-β-synthase (CBS), cystathionine-γ-lyase, and 3-mercaptopyruvate sulfurtransferase. Although many of these compounds have their limitations (potency, selectivity), these molecules, especially in combination with genetic approaches, can be instrumental for the delineation of the biologic processes involving endogenous H2S production. Moreover, some of these compounds (e.g., cell-permeable prodrugs of the CBS inhibitor aminooxyacetate, or benserazide, a potentially repurposable CBS inhibitor) may serve as starting points for future clinical translation. The present article overviews the currently known H2S donors and H2S biosynthesis inhibitors, delineates their mode of action, and offers examples for their biologic effects and potential therapeutic utility.

Therapeutic potential of hydrogen sulfide in osteoarthritis development

Hydrogen Sulfide as a Potential Therapeutic Target in Fibrosis

Hydrogen Sulfide Protects Against IL‐1β‐induced Inflammation and Mitochondrial Dysfunction‐related Apoptosis in Chondrocytes and Ameliorates Osteoarthritis

Hydrogen Sulfide Attenuates Il-1 Beta-Induced Inflammatory Signaling And Dysfunction Of Osteoarthritic Chondrocytes

Hydrogen sulfide donors: Therapeutic potential in anti-atherosclerosis

New Therapeutic Approaches Using Hydrogen Sulfide Donors in Inflammation and Immune Response

Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities

The protective role of the 3-mercaptopyruvate sulfurtransferase (3-MST)-hydrogen sulfide (H2S) pathway against experimental osteoarthritis

P42Hydrogen Sulfide is a Promising Therapeutic Strategy for Atherosclerosis

Atherosclerosis And The Hydrogen Sulfide Signaling Pathway - Therapeutic Approaches To Disease Prevention

Hydrogen Sulfide in Bone Tissue Regeneration and Repair: State of the Art and New Perspectives

Hydrogen sulfide protects MC3T3-E1 osteoblastic cells against H 2O2-induced oxidative damage-implications for the treatment of osteoporosis

Therapeutic applications of organosulfur compounds as novel hydrogen sulfide donors and/or mediators.

Hydrogen Sulfide: A Versatile Molecule and Therapeutic Target in Health and Diseases

Hydrogen Sulfide and Translational Medicine

Can Hydrogen Retard the Progression of Osteoarthritis

Hydrogen Sulfide Interacting with Cannabinoid 2 Receptors during Sciatic Nerve Injury-Induced Neuropathic Pain

Current Status and Future Prospects of Hydrogen Sulfide Donor‐Based Delivery Systems

Injectable spontaneous hydrogen-releasing hydrogel for long-lasting alleviation of osteoarthritis

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors

Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter